A recent study has demonstrated that the high expression of nerve growth factor receptors on tumor cells predicts anti-PD-1 therapy resistance in patients with melanoma (11), which provides evidence for the correlation between neural signaling and immunotherapy responses. This evidence concerns the gene PDCD1 and neoplasm.